[1]Patent:EP1961734,2008,A1.Locationinpatent:Page/Pagecolumn36
[1]Patent:EP1961734,2008,A1.Locationinpatent:Page/Pagecolumn35
[1]Patent:EP1961734,2008,A1.Locationinpatent:Page/Pagecolumn64
[1]Patent:EP1961734,2008,A1.Locationinpatent:Page/Pagecolumn35
[1]Patent:US2019/161432,2019,A1.Locationinpatent:Paragraph0083;0092;0093
Title: Amiselimod, a novel sphingosine 1-phosphate receptor-1 modulator, has potent therapeutic efficacy for autoimmune diseases, with low bradycardia risk.
Journal: British journal of pharmacology 20170101
Title: Sugahara K et al. Amiselimod, a novel sphingosine 1-phosphate receptor-1 modulator, has potent therapeutic efficacy for autoimmune diseases, with low bradycardia risk. Br J Pharmacol. 2016 Oct 7.
Title: Kappos L et al. Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2016 Oct;15(11):1148-59.
